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erature. A three-year intervention was assumed with outcomes
of: 1) a -year duration of effect; and 2) a lifetime duration of
effect. A second set of models included an additional increased
cost of illness for obese NGT subjects, and an increased mortal-
ity rate for obese T2DM subjects over the base-case. RESULTS:
Lifestyle dominated placebo in all models tested. In the obesity-
adjusted model, subjects had higher lifetime costs and shorter
duration of life. The following incremental cost-effectiveness
ratios were derived: 1) base-case model - three-year duration 
= -$16,064/LY; 2) base-case model - lifetime duration =
-$19,496; 3) obesity-adjusted model - three-year duration =
-$2278/LY; and 4) obesity-adjusted model - lifetime duration 
= -$4281/LY. A maximal acceptable cost of intervention per year
for the three-year duration of effect that could be used to main-
tain lifestyle dominance was also established. The value for the
obesity-adjusted model was approximately 45% of that found
for the base-case model. CONCLUSION: Researchers examin-
ing the cost-effectiveness of intensive lifestyle intervention to
prevent T2DM should be aware of the potential effect of obesity
adjustments when developing models, in particular, the effects of
obesity on mortality and costs for NGT subjects.
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OBJECTIVE: Cost models are often criticized for limited or
obscure selection of transition probabilities, especially when
several estimates are available. We conducted a systematic review
of population-based studies estimating the impact of improved
glycemic control on the incidence of microvascular (retinopathy,
nephropathy, and neuropathy/diabetic sores and ulcers/lower
extremity amputations(LEA)) and macrovascular (myocardial
infarction and stroke) complications of type-2 diabetes mellitus.
METHODS: Literature searches using keyword and MESH algo-
rithms in the PubMed bibliographic database, and hand search.
Studies had to be published between 1985–2004, conducted in
Australia, North America, or Europe, and compare the risk for
macrovascular or microvascular complications per % difference
in HbA1c over three to ten years. Two reviewers independently
extracted study and population characteristics and the relative
risk (RR) associated with a 1% crude difference in HbA1c.
Odds-ratios were treated as RRs. Meta-analytic pooled estimates
were calculated for complications with more than one RR esti-
mate using random effects models. To account for variation in
study design validity cohort and experimental studies were
weighted twice as much as cross-sectional studies. RESULTS:
RR estimates were obtained for retinopathy (eight estimates),
nephropathy (four), all-cause mortality (two), myocardial infarc-
tion (one), diabetic sores and ulcers (one), and LEA (one). No
RR estimate was identiﬁed for stroke. A crude 1% difference in
HbA1c was found to reduce the likelihood of retinopathy by
25% (95% CI: 19%–30%), nephropathy by 22% (13%–32%),
all-cause mortality by 17% (10%–27%), myocardial infarction
by 16% (9%–27%), diabetic sores and ulcers by 30%
(20%–50%), and LEA by 30% (10%–50%). CONCLUSIONS:
A crude 1% decrease in HbA1c leads to a signiﬁcant reduction
in the incidence of serious diabetic complications. Epidemiologic
studies were surprisingly scarce, especially for macrovascular
complications and population subgroups. Laboratory-enriched
claims databases would be ideal for future studies relating
HbA1c to diabetic complications.
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OBJECTIVES: To estimate the treatment costs incurred by
Alzheimer’s disease (AD) patients in Medi-Cal over an eight-year
span (1995–2002). METHODS: AD patients were identiﬁed
(ICD-9 = 331.0) using 20% sample of Medi-Cal administrative
claims data from January 1, 1995 to December 31, 2002, and
were 1 :10 matched to the a control group without AD diagno-
sis based on age and gender. Annual total treatment costs were
calculated for both groups. For patients with AD, yearly expen-
ditures after the initial diagnosis were also measured. All costs
were eligibility-adjusted by the number of eligible months.
RESULTS: In total, 6494 cases and 64,940 controls were iden-
tiﬁed. The average age was 83.6 (+/-12.2) and 69.5% were
female. The average annual treatment costs were more than two-
fold higher for AD patients than controls ($13,978 vs. $6188, 
p < 0.0001). Without adjusting for inﬂation, the treatment costs
for a typical AD patient increased from $10,032 in 1995 to
$19,446 in 2002. During the ﬁrst year after the initial diagno-
sis, the average treatment costs for AD was $17,725. The costs
increased slightly over time for those patients who survived and
remained in Medi-Cal and by the fourth year, the treatment costs
increased to $18,064. For the ﬁrst year, nursing home costs
accounted 81% of the total costs, followed by pharmacy (8%)
then outpatient (6%). For AD alone, it is estimated that Medi-
Cal paid an incremental $84 million in 1995 and $200 million
in 2002. CONCLUSIONS: This study demonstrated that AD is
an increasingly costly disease, and treatment costs were doubled
from 1995–2002. Consistent with previous studies, nursing
home care was the major component of health care costs.
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OBJECTIVES: To assess the one-year direct mental health costs
of treating crisis-prone schizophrenia patients. METHODS:
Data were drawn from a large multi-site prospective naturalistic
study of schizophrenia patients in the United States, conducted
between July, 1997 and September, 2003. Participants were
treated at large mental health systems, including the Veterans
Health Administration, community health centers, community
and state hospitals, and university health care delivery systems.
Total mental health cost and component costs (psychiatric 
hospitalizations, antipsychotic medications, other psychotropic
medications, day treatment, emergency psychiatric services, psy-
chosocial/rehabilitation group therapy, individual therapy, med-
ication management, and case management), were calculated for
1557 participants with complete medical information. Propen-
sity score adjusted bootstrap re-sampling methods were used to
compare one-year direct costs of ﬁve crisis-prone subgroups,
deﬁned as having: prior suicide attempt (in past four weeks,
yes/no), psychiatric hospitalization (in past six months, yes/no),
prior arrest (in past six months, yes/no), prior violent behaviors
